That is predominantly because of discovery of point mutations in IDH1 or IDH2 in certain leukemia and GBM; these mutations alter the activity of the enzyme. I would love to talk in details about this, but am currently busy doing something else. Refer to this review instead: Losman & Kaelin, G&D 27:836-852, 2013.